In today's rapidly evolving AI landscape, I offer specialized consulting services to businesses of all sizes, focusing on reshaping their strategic approach to leverage cutting-edge technologies. With my diverse background, which includes an MIT degree in Applied Data Science, expertise in Internal Medicine, and an Executive MBA, I bring a unique blend of technical, medical, and business acumen to the table. My approach involves closely collaborating with clients to set precise operational objectives, guiding them through each phase of their digital transformation journey. By integrating advanced data analytics and AI insights into their core operations, I help companies optimize their processes, innovate in their respective fields, and stay ahead in the competitive market. My services are especially valuable for organizations looking to navigate the complexities of AI implementation and leverage it for sustainable growth and efficiency.

I was appointed “global clinical development lead” for acute care including cardiology, oncology and muscle related conditions. My focus was clinical development and BD support. I build several "evidence development plan" for various molecular entities (synthetic, natural). It implied cross-functional discussions with both R&D and market access (including focus groups). Specifically: - Cardiology: I led the Nestlé team that acquired an exclusive license for a new galectin-3 inhibitor (G-Pharmaceuticals) for heart failure. This G3 inhibitor of fibrosis process was at the pre-clinical stage. After the acquisition, I joined the steering committee and the project team. Together with G3 pharmaceuticals CEO, I designed the first in man study: a Single Ascending Dose (SAD) followed by a Multiple Ascending Dose (MAD). - Muscle related conditions: Nestlé is very active in the field of muscle related conditions and has a full R&D department working on muscle physiology. a) Muscle injury: Together with RD, I designed, wrote synopsis and protocol for a First In Man/Proof Of Concept study in a model of muscle injury in healthy volunteers. This model include the provocation of a muscle with electrostimulation followed by muscle biopsies. Nicotinamide (NAM) and Pyridoxine (Vitamin B6) on Muscle Regeneration (NCT04874662) b) Mitochondria co-factor: I designed a FIM with muscle biopsies in healthy volunteers for a co-factor used by mitochondria for the production of energy. Together with an expert in PK/PD modeling (I recruited him), we set-up a PK model for single and multiple doses simulations.- Aging: I launched a POC clinical trial in a CRO in Germany. I acted as a medical monitor. I visited the CRO and performed the initiation visit with the CRA. I assessed the Adverse Events during the course of the study.- Dysphagia. Together with Professor Pere Clavè, I designed a study in 2 parts for assessing the effectiveness of TickenClear for dysphagia (NCT04741581).

"Clinical development, medical affairs, regulatory strategy, data science, pharmacovigilance and good clinical practice compliance in the field of Antibiotic Multi Resistant bacteria (AMR) and phage therapy. Under the direction of Gunther Vanwezer CEO, I helped as CMO Vésale Bioscience to revisit its clinical development for its phagogram named Luminophage (IVDR) and its overall clinical development plan. I also gave some regulatory advice for phage therapy "access to market" working closely with the head of marketing (CCO - Philippe Ghem). It was a great experience with a fantastic team fighting against antibiotic multiresistant bacterias."

I was in a short mission to evaluate and to set-up strategies to enhance digital innovation in the SwissEcosytem in general and in the Vaud ecosystem in particular. I concluded this mission with a presentation on digital health and machine learning. This was a fantastic opportunity for me to increase my Swiss network and to observe the launch of H4, a laboratory for launching innovation in health care. Dr Vincent Grek

As specialist in Internal Medicine, trained in intensive care and hemato-oncology and in bone marrow transplantation, Dr Vincent Grek is currently fully registered for practicing in France (RPPS 10001620201, Belgium (INAMI 18124449580) and, recently, in Switzerland (GLN7601007828579). • Internal Medicine Cabinet Dr Grek, Lausanne, Suisse 2020-Now• General Internal Medicine CH Soignies, revalidation, Belgium 2017-2018• Internal Medicine Interim Director CHU Tivoli Biobank, Belgium 2016-2017• General Internal Medicine CH Nivelles, internal medicine, Belgium 2014-2016• Internal Medicine Private Consultancy, Paris, France 2003-2014• Clinical Phase Unit 1 Medical director, CPU, Leiden, Holland 1998-2003• Internal Medicine Intensive care, Belgium 1996-1998• Infectious diseases Academic Hospital, Utrecht, Holland 1996-1996• Head of intensive care General hospital, Saint-Odes, Belgium 1994-1996• Internal medicine Academic Hospital, Liège, Belgium 1989-1994

During my Executive MBA at ESSEC, I founded Only for Chlidren Pharmaceuticals (O4CP). The company was named as I have 4 children. At O4CP, we developped a new innovative device called "the shaker". The value proposition was "to give to the children the drug they need, with the taste they like, with pediatric security". We designed and patented this device with 2 caps. After having obtained orphan designations in EMA and US, we explored a methotrexate liquid formulation in children with acute lymphoblastic leukemia. This program was largely funded by a Frame Program 7 grant named "Loulla&Philla". It is noticeable that the Loulla&Philla received the best mark 15/15 on its evaluation: 5 for the innovation, 5 for its consortium and 5 for the expected impact. We also engaged in the development of an IV formulation for neonatal seizures. The program was also funded. I am grateful of Alice Nolla (Responsible Pharmacist), Morgan Danvel (Project Manager) and Estelle Habert-Ortoly (Business Manager) who engaged in this start-up adventure. O4CP was not a commercial success. It had many positive outcomes: publications, IP, people development (Alice acquired her “type B” pharmacist license; many young pharmacist were trained to pediatric development), development of quality systems (GMP, GCP), several orphan designations, IPO preparation and much more.